RARE
Ultragenyx Pharmaceutical Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-29/100
Last price
14.47
▼ 0.03 (0.21%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
14.74
Prev close
14.50
Day high
14.70
Day low
14.08
Volume
3.89M
Market cap
$1.43B
P/E (TTM)
—
52W range
12.73 – 39.89
Day trading desk
Gap from prior close
+1.66%
Prior close 14.50
VWAP
14.47
+0.02% from price
Relative volume
1.78×
Unusually busy
Session range
4.69%
14.08 – 14.74
Position in range
59%
Mid range
ATR (14D)
0.91
6.26% of price
Prior day high
15.31
PDH
Prior day low
14.21
PDL
Bid / ask spread
—
Quote not published
Session volume
6.73M
Avg 3.79M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.61%
-7.6%
1M
-5.49%
-6.6%
3M
-58.29%
-62.8%
6M
-37.54%
-55.7%
YTD
-37.13%
-51.4%
1Y
-53.67%
-70.1%
3Y
-59.44%
-141.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RARE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+292.56K
Net buying
Buy transactions
15
324.61K shares
Sell transactions
11
32.06K shares
Net transactions
+26
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
3.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | HUIZENGA THEODORE ALAN Officer |
SELL | 1.28K | $17.41K | Direct |
| Sep 3, 26 | HUIZENGA THEODORE ALAN Officer |
SELL | 161 | $2.25K | Direct |
| Aug 3, 26 | PARSCHAUER KARAH HERDMAN Officer |
SELL | 1.90K | $47.35K | Direct |
| Aug 3, 26 | HORN HOWARD Chief Financial Officer |
SELL | 4.70K | $117.02K | Direct |
| Jul 1, 26 | HORN HOWARD Chief Financial Officer |
SELL | 4.70K | $155.65K | Direct |
| Jun 15, 26 | PARSCHAUER KARAH HERDMAN Officer |
SELL | 1.90K | $46.75K | Direct |
| Jun 15, 26 | SANDERS CORAZON CORSEE D Director |
SELL | 2.00K | $50.10K | Direct |
| Jun 1, 26 | HORN HOWARD Chief Financial Officer |
SELL | 4.65K | $110.60K | Direct |
| May 18, 26 | SULIMAN SHEHNAAZ Director |
SELL | 5.74K | $144.19K | Direct |
| May 14, 26 | FUST MATTHEW K. Director |
STOCK | 7.75K | $0 | Direct |
| May 14, 26 | WELCH DANIEL G Director |
STOCK | 7.75K | $0 | Direct |
| May 14, 26 | SULIMAN SHEHNAAZ Director |
STOCK | 7.75K | $0 | Direct |
| May 14, 26 | SANDERS CORAZON CORSEE D Director |
STOCK | 7.75K | $0 | Direct |
| May 14, 26 | RAY AMRIT Director |
STOCK | 7.75K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CROMBEZ ERIC M.D. |
Officer | 111.19K | Sale |
HARRIS ERIK |
Officer | 118.41K | Stock Award(Grant) |
HORN HOWARD |
Chief Financial Officer | 96.30K | Sale |
HUANG DENNIS KARL |
Chief Technology Officer | 147.84K | Stock Award(Grant) |
HUIZENGA THEODORE ALAN |
Officer | 67.86K | Sale |
KAKKIS EMIL D |
Chief Executive Officer | 2.89M | Stock Award(Grant) |
KASSBERG THOMAS RICHARD |
Chairman of the Board | 264.73K | Sale |
PARSCHAUER KARAH HERDMAN |
Officer | 92.56K | Sale |
PINION JOHN RICHARD |
Officer | 133.14K | Stock Award(Grant) |
WELCH DANIEL G |
Director | 40.44K | Stock Award(Grant) |
Fundamentals
Market cap$1.43B
Enterprise value$2.34B
Revenue (TTM)$717.00M
Gross profit$-149.00M
EBITDA$-465.00M
Net income$-586.00M
EPS (TTM)$-5.80
Free cash flow$-221.79M
Total cash$292.00M
Total debt$1.20B
Book value / share$-2.96
Shares outstanding98.59M
Float80.42M
Short % of float17.38%
Dividend yield0.00%
Beta (5Y)0.35
Valuation & profitability ratios
Trailing P/E—
Forward P/E21.37
PEG ratio—
Price / sales—
Price / book—
EV / revenue3.26
EV / EBITDA-5.03
Gross margin-20.78%
Operating margin-35.05%
Profit margin-81.73%
Return on equity—
Return on assets-24.22%
Debt / equity—
Current ratio1.73
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $673.00M | $560.00M | $434.00M | $363.33M | +20.2% |
| Operating revenue | $673.00M | $560.00M | $434.00M | $363.33M | +20.2% |
| Cost of revenue | $109.00M | $77.00M | $45.00M | $28.32M | +41.6% |
| Gross profit | $564.00M | $483.00M | $389.00M | $335.01M | +16.8% |
| Research & development | $750.00M | $698.00M | $648.00M | $705.79M | +7.4% |
| Selling, general & admin | $349.00M | $321.00M | $310.00M | $278.14M | +8.7% |
| Total operating expense | $1.10B | $1.02B | $958.00M | $983.93M | +7.9% |
| Operating income | -$535.00M | -$536.00M | -$569.00M | -$648.92M | +0.2% |
| Net interest income | -$37.00M | -$26.00M | -$39.00M | -$31.94M | -42.3% |
| Pre-tax income | -$571.00M | -$567.00M | -$609.00M | -$701.73M | -0.7% |
| Tax provision | $4.00M | $2.00M | -$2.00M | $5.70M | +100.0% |
| Net income | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -1.1% |
| Net income to common | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -1.1% |
| Basic EPS | -5.83 | -6.29 | -8.25 | -10.12 | +7.3% |
| Diluted EPS | -5.83 | -6.29 | -8.25 | -10.12 | +7.3% |
| EBIT | -$509.00M | -$504.00M | -$543.00M | -$658.71M | -1.0% |
| EBITDA | -$474.00M | -$468.00M | -$517.00M | -$640.49M | -1.3% |
| Basic shares | 98.60M | 90.54M | 73.54M | 69.91M | +8.9% |
| Diluted shares | 98.60M | 90.54M | 73.54M | 69.91M | +8.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $421.00M | $174.00M | $213.58M | $132.94M | +142.0% |
| Cash & short-term investments | $680.00M | $610.00M | $577.21M | $747.76M | +11.5% |
| Accounts receivable | $158.00M | $122.00M | $73.39M | $40.45M | +29.5% |
| Inventory | $52.00M | $45.00M | $33.97M | $26.77M | +15.6% |
| Total current assets | $951.00M | $817.00M | $732.18M | $883.90M | +16.4% |
| Property, plant & equipment | $244.00M | $266.00M | $290.57M | $259.73M | -8.3% |
| Goodwill & intangibles | $220.00M | $222.00M | $210.68M | $204.51M | -0.9% |
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | +1.9% |
| Total current liabilities | $384.00M | $344.00M | $280.44M | $261.21M | +11.6% |
| Total debt | $36.00M | $40.00M | $43.17M | $31.59M | -10.0% |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | +29.3% |
| Retained earnings | -$4.53B | -$3.96B | -$3.39B | -$2.78B | -14.5% |
| Shareholder equity | -$80.00M | $255.00M | $275.41M | $352.49M | -131.4% |
| Working capital | $567.00M | $473.00M | $451.75M | $622.69M | +19.9% |
| Net tangible assets | -$300.00M | $33.00M | $64.74M | $147.98M | -1,009.1% |
| Shares issued | 96.65M | 92.55M | 82.33M | 70.20M | +4.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -1.1% |
| Depreciation & amortisation | $35.00M | $36.00M | $26.00M | $18.22M | -2.8% |
| Stock-based compensation | $153.00M | $158.00M | $135.00M | $130.38M | -3.2% |
| Change in working capital | -$23.00M | $14.00M | -$16.00M | $60.23M | -264.3% |
| Operating cash flow | -$466.00M | -$414.00M | -$475.00M | -$380.46M | -12.6% |
| Capital expenditure | -$21.00M | -$20.00M | -$47.00M | -$146.12M | -5.0% |
| Investing cash flow | $236.00M | -$18.00M | $168.00M | -$291.65M | +1,411.1% |
| Financing cash flow | $478.00M | $399.00M | $388.00M | $501.21M | +19.8% |
| Free cash flow | -$487.00M | -$434.00M | -$522.00M | -$526.59M | -12.2% |
| End cash position | $436.00M | $184.00M | $219.00M | $137.60M | +137.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $214.00M | $136.00M | $207.28M | $159.93M | $167.00M | +57.4% |
| Operating revenue | $214.00M | $136.00M | $207.28M | $159.93M | $167.00M | +57.4% |
| Cost of revenue | $34.00M | $30.00M | $29.34M | $27.99M | $23.00M | +13.3% |
| Gross profit | $180.00M | $106.00M | $177.93M | $131.94M | $144.00M | +69.8% |
| Research & development | $167.00M | $187.00M | $203.28M | $216.21M | $165.00M | -10.7% |
| Selling, general & admin | $88.00M | $88.00M | $87.94M | $86.62M | $87.00M | 0.0% |
| Total operating expense | $255.00M | $275.00M | $291.22M | $302.83M | $252.00M | -7.3% |
| Operating income | -$75.00M | -$169.00M | -$113.28M | -$170.89M | -$108.00M | +55.6% |
| Net interest income | -$17.00M | -$15.00M | -$12.96M | -$8.29M | -$8.00M | -13.3% |
| Pre-tax income | -$91.00M | -$184.00M | -$127.69M | -$179.54M | -$114.00M | +50.5% |
| Tax provision | $1.00M | $1.00M | $870.00K | $873.00K | $1.00M | 0.0% |
| Net income | -$92.00M | -$185.00M | -$128.56M | -$180.41M | -$115.00M | +50.3% |
| Net income to common | -$92.00M | -$185.00M | -$128.56M | -$180.41M | -$115.00M | +50.3% |
| Basic EPS | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 | +51.1% |
| Diluted EPS | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 | +51.1% |
| EBIT | -$69.00M | -$163.00M | -$108.22M | -$165.39M | -$100.00M | +57.7% |
| EBITDA | -$61.00M | -$155.00M | -$99.43M | -$157.18M | -$91.00M | +60.6% |
| Basic shares | 101.90M | 100.60M | 99.90M | 99.77M | 98.46M | +1.3% |
| Diluted shares | 101.90M | 100.60M | 99.90M | 99.77M | 98.46M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $125.00M | $175.00M | $421.00M | $202.51M | $166.11M | — | -28.6% |
| Cash & short-term investments | $292.00M | $413.00M | $680.00M | $425.25M | $477.38M | — | -29.3% |
| Accounts receivable | $200.00M | $121.00M | $158.00M | $112.54M | $124.46M | — | +65.3% |
| Inventory | $59.00M | $55.00M | $52.00M | $52.20M | $46.50M | — | +7.3% |
| Total current assets | $606.00M | $657.00M | $951.00M | $643.21M | $719.79M | — | -7.8% |
| Property, plant & equipment | $235.00M | $239.00M | $244.00M | $249.96M | $255.76M | — | -1.7% |
| Goodwill & intangibles | $216.00M | $218.00M | $220.00M | $217.35M | $219.14M | — | -0.9% |
| Total assets | $1.26B | $1.30B | $1.53B | $1.19B | $1.31B | — | -2.5% |
| Total current liabilities | $351.00M | $325.00M | $384.00M | $340.02M | $293.24M | — | +8.0% |
| Total debt | — | — | $36.00M | $33.83M | $36.30M | $38.27M | — |
| Total liabilities | $1.55B | $1.52B | $1.60B | $1.17B | $1.15B | — | +1.5% |
| Retained earnings | -$4.81B | -$4.72B | -$4.53B | -$4.40B | -$4.22B | — | -2.0% |
| Shareholder equity | -$291.00M | -$236.00M | -$80.00M | $9.16M | $151.29M | — | -23.3% |
| Working capital | $255.00M | $332.00M | $567.00M | $303.18M | $426.54M | — | -23.2% |
| Net tangible assets | -$507.00M | -$454.00M | -$300.00M | -$208.19M | -$67.85M | — | -11.7% |
| Shares issued | 98.60M | 98.62M | 96.65M | 96.62M | 96.53M | — | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$92.00M | -$185.00M | -$128.56M | -$180.44M | -$115.00M | — | +50.3% |
| Depreciation & amortisation | $8.00M | $8.00M | $8.79M | $8.21M | $9.00M | — | 0.0% |
| Stock-based compensation | $34.00M | $30.00M | $37.29M | $37.71M | $38.00M | — | +13.3% |
| Change in working capital | -$29.00M | -$51.00M | $588.00K | $55.41M | -$23.00M | — | +43.1% |
| Operating cash flow | -$97.00M | -$197.00M | -$99.83M | -$91.17M | -$109.00M | — | +50.8% |
| Capital expenditure | -$1.00M | -$6.00M | -$938.00K | -$1.06M | -$3.00M | — | +83.3% |
| Investing cash flow | $44.00M | -$49.00M | -$72.25M | $117.25M | $71.00M | — | +189.8% |
| Financing cash flow | — | — | $394.19M | -$192.00K | $83.65M | $157.00K | — |
| Free cash flow | -$98.00M | -$203.00M | -$100.77M | -$92.23M | -$112.00M | — | +51.7% |
| End cash position | $140.00M | $189.00M | $436.00M | $214.70M | $189.00M | — | -25.9% |
Options analytics
Put / call volume
3.85
Put-heavy session
Put / call open interest
2.05
Positioning, not flow
Max pain
13.50
-6.6% from spot
ATM implied vol
103.9%
Nearest strike to spot
Skew (10% OTM)
+8.6%
Puts bid over calls
Call volume
41
Contracts, this expiry
Put volume
158
Contracts, this expiry
Heaviest call OI
15.50
55 contracts
Heaviest put OI
13.00
96 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.00 | -0.90 | +9.7% |
| Mar 2026 | -1.46 | -1.54 | -5.7% |
| Dec 2025 | -1.17 | -1.29 | -10.1% |
| Sep 2025 | -1.21 | -1.81 | -49.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.65 | 5 | $184.49M | +15.4% |
| Next quarter | -0.57 | 5 | $232.73M | +12.4% |
| Current year | -3.87 | 5 | $762.99M | +13.4% |
| Next year | 0.68 | 5 | $1.00B | +31.2% |
Analyst targets & ownership
Mean target$28.05
High target$40.00
Low target$18.00
Implied upside93.87%
Analyst count19
ConsensusBUY
Strong buy / Buy2 / 9
Hold9
Sell / Strong sell0 / 0
Held by insiders3.44%
Held by institutions112.49%
Institutions holding434
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.78
-2.12% from price
SMA 20
14.48
-0.17% from price
SMA 50
20.69
-30.12% from price
SMA 100
24.00
-39.72% from price
SMA 200
23.89
-39.48% from price
EMA 12
14.95
-3.19% from price
EMA 26
16.64
-13.02% from price
EMA 50
19.42
-25.47% from price
RSI (14)
35.3
Neutral
MACD (12,26,9)
-1.69
Hist 0.45
ATR (14)
0.91
6.27% of price
Realised vol 30D
175.1%
Annualised
Bollinger upper
15.79
20, 2σ
Bollinger lower
13.18
20, 2σ
50 / 200 cross
Death
20.69 vs 23.89
Trend bias
Below 200
-39.48%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.24
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
175.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.8%
Peak to trough
Max drawdown 5Y
-85.3%
Peak to trough
ATR 14
0.91
6.27% of price
Beta (reported)
0.35
5Y monthly, from filing
Short interest
Shares short
16.57M
Prior 15.89M
Change vs prior
+4.3%
Shorts adding
% of float
17.38%
Elevated
% of shares out
16.81%
Against total outstanding
Days to cover
3.5
Liquid
Float
80.42M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Oct 21, 24 | TD Cowen | MAINTAINED | Buy | Buy |
| Oct 1, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 26, 24 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 20, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Sep 16, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 5, 24 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 2, 24 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 2, 24 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Aug 2, 24 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 2, 24 | Wedbush | MAINTAINED | Neutral | Neutral |
| Jul 23, 24 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-19
Corporate Changes & Voting Matters
8-K · 2026-08-11
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-08-04
Offering Registrations
S-8 · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-18
Headlines
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?
Simply Wall St. · 4h ago
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Zacks · 2d ago
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
GlobeNewswire · 5d ago
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
Stocktwits · 14d ago
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Insider Monkey · 15d ago
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
Simply Wall St. · 18d ago
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Zacks · 19d ago
/C O R R E C T I O N -- Andelyn Biosciences/
PR Newswire · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.